Navigation Links
Herding cancer cells to their death
Date:6/20/2013

June 20, 2013, New York, NY and Oxford, UK An advanced tumor is a complex ecosystem. Though derived from a single cell, it evolves as it grows until it contains several subspecies of cells that vary dramatically in their genetic traits and behaviors. This cellular heterogeneity is what makes advanced tumors so difficult to treat. Publishing their findings in today's online issue of Cancer Cell, an international team of scientists led jointly by Professors Colin Goding from the Ludwig Institute for Cancer Research who is based at the University of Oxford and Jos Neptuno Rodriguez-Lpez from the University of Murcia, Spain describe a therapeutic strategy that manipulates a mechanism driving that heterogeneity to treat advanced melanoma. Their preclinical studies show that the strategy, which employs a new drug-like molecule in combination with an existing chemotherapy, is highly specific to melanoma cells and effective against tumors that resist all other therapies.

If caught early, melanoma is relatively easy to treat. But in its late stages, it is a stubborn and deadly cancer. Until about a decade ago, patients survived only about seven months after starting treatment. Since then, therapies, such as vemurafenib, that specifically target signaling proteins essential to the proliferation and survival of melanoma cells have extended the lives of some patients. But only about half respond to these targeted therapies, and even in those patients the cancer begins to resist the targeted therapy within six to nine months.

To bypass such resistance, the researchers developed a strategy that essentially pushes subtypes of melanoma cells that are not dividingand are therefore not susceptible to chemotherapyto become vulnerable to a shrewdly targeted drug.

To develop their therapy, the scientists first screened a variety of molecules to find one that boosts the expression of MITF, a master gene that, at high levels, pushes melanoma cell
'/>"/>

Contact: Rachel Steinhardt
rsteinhardt@licr.org
212-450-1582
Ludwig Institute for Cancer Research
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. No danger of cancer through gene therapy virus
2. An article in Cell reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer
3. Osteoporosis drug stops growth of breast cancer cells, even in resistant tumors
4. Using math to kill cancer cells
5. Gene variants may predict who will benefit from breast cancer prevention drugs
6. Nanotechnology helps track and improve drug action in pancreatic cancer
7. Biomarker identification may lead to new noninvasive test for colorectal cancer detection
8. First dual-action compound kills cancer cells, stops them from spreading
9. New Research: Modified Citrus Pectin - A Potent Anti-Cancer Therapy
10. U of A medical researchers ID genetic marker for sporadic breast cancer
11. Modulating the immune system to combat metastatic cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... – Accurate knowledge regarding Ebola is critical and pertinent ... of hazardous global outbreak and epidemic. The Journal, ... a special issue, Ebola Virus and Public Health, to ... knowledge in this critical societal moment. , On ... Ebola for Clinicians . The primer was prepared by ...
(Date:10/17/2014)... of Copenhagen have shown for the first time how ... fibrosis patients, giving them the opportunity to get tremendous ... , The study also discovered the bacterial growth in ... halted or slowed down by the immune cells. The ... and helped "suffocate" the bacteria, forcing the bacteria to ...
(Date:10/16/2014)... Cancer constantly wages war on the human body. ... a stalemate. In pancreatic cancer, this stalemate—known as ... becoming aggressively malignant, a phenomena that is poorly ... in the laboratory of Salvatore Torquato, a Professor ... the conditions surrounding tumor dormancy and the switch ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Modeling tumor dormancy 2
... have bacteria in their guts that may predispose them to ... University of California, Berkeley, and the University of Arizona, Tucson. ... than a thousand people from around the world showed that ... have been linked to obesity than did people living farther ...
... whether or not they end up feeding on a particular ... which that plant belongs. The quality of the individual plant ... of other plants growing around it. But what, ultimately, makes ... question ecologists have struggled with for decades, and the answer ...
... Arctic wildlife and landscapes are crucially at risk due ... the Arctic Biodiversity Assessment (ABA), a new report prepared ... of the Conservation of Arctic Flora and Fauna (CAFF), ... "An entire bio-climatic zone, the high Arctic, may disappear. ...
Cached Biology News:Geographic variation of human gut microbes tied to obesity 2Geographic variation of human gut microbes tied to obesity 3'Neighbor-plants' determine insects' feeding choices 2Arctic biodiversity under serious threat from climate change according to new report 2Arctic biodiversity under serious threat from climate change according to new report 3
(Date:10/20/2014)... Earle Martin , Chief ... that Ellen Teplitzky, an experienced attorney specializing in ... industry, has joined the firm as Director of ... practice. NDA Partners provides legal services, including ... to top law firms and their clients in ...
(Date:10/19/2014)... NextCODE Health, which enables clinicians and researchers to use full ... the launch of its new genomic data analysis and collaboration ... of Human Genetics (ASHG) annual meeting in San ... for free beta access, visit www.nextcode.com . A brief ... here . The Exchange: , ...
(Date:10/19/2014)... The report "Chocolate, Cocoa Beans, Lecithin, ... Geography Trend and Forecast (2011 - 2016)," analyzes ... and studies the major market drivers, restraints, and opportunities ... Asia. , The global chocolate market is expected to ... 2016 at an estimated CAGR of 2.7% from 2011 ...
(Date:10/18/2014)... The “Human Insulin Market- by ... Premixed), Modern Human Insulin (Rapid Acting, Long Acting, ... Tresiba, Others) - Forecast to 2018” provides a ... opportunities, current market trends, and strategies impacting the ... and forecasts of the revenue and share analysis. ...
Breaking Biology Technology:NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 5
... at the latest new drugs. Pharma Opinions unveils a new site ... and commented. , ... Costa de Caparica, Portugal (PRWEB) October 21, 2008 ... in the U.S. Pharma Opinions unveils a new site were top notch ...
... Mass., Oct. 21 Boston Scientific,Corporation (NYSE: BSX ) ... 2008, as well as guidance for net sales and,earnings per ... Third quarter highlights: -- Reported net sales of $1.978 ... drug-eluting stent (DES) market leadership -- Achieved worldwide cardiac ...
... over third quarter 2007 to $201 million, SAN ... ) today reported financial results for the quarter ended,September ... million,for the third quarter, including net product sales of ... 2007. Net loss for the quarter ended,September 30, 2008 ...
Cached Biology Technology:Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 2Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 3Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 4Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 5Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 6Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 7Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 8Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 9Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 10Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 11Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 12Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 13Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 14Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 15Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 16Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 17Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 18Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 19Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 20Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 21Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 22Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 23Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 24Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 25Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 26Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 27Amylin Pharmaceuticals Reports Third Quarter Financial Results 2Amylin Pharmaceuticals Reports Third Quarter Financial Results 3Amylin Pharmaceuticals Reports Third Quarter Financial Results 4Amylin Pharmaceuticals Reports Third Quarter Financial Results 5Amylin Pharmaceuticals Reports Third Quarter Financial Results 6Amylin Pharmaceuticals Reports Third Quarter Financial Results 7Amylin Pharmaceuticals Reports Third Quarter Financial Results 8
... antibody to the Salmonella Common Structural Antigens ... a serum pool of goats immunized with ... is broadly reactive to Salmonella and recognizes ... has excellent specificity for Group B and ...
Lysozyme C (W-20)...
... ,Each upright model provides fast pull-down, ... uniformity for refrigerated blood. The BBR25 and ... for complete blood storage monitoring. Models BBR6, ... the HemaPro 101 alarm/monitor. All of these ...
... RNase H- Reverse Transcriptase ... version of SuperScript™ II ... SuperScript™ II it synthesizes ... from single-stranded RNA DNA ...
Biology Products: